Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.68 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14254668 | 0.89 | CYP2B6 (0.59) | CYP2B6TBXAS1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL7664060 | 0.89 | CYP2B6 (0.59) | CYP2B6TBXAS1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL14254664 | 0.89 | CYP2B6 (0.59) | CYP2B6TBXAS1CYP19A1CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL17048494 | 0.88 | CYP2B6 (0.57) | CYP2B6TBXAS1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL3019994 | 0.86 | — | — | |
| SCHEMBL11051252 | 0.82 | CYP2B6 (0.89) | CYP2B6TBXAS1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL11047050 | 0.82 | CYP2B6 (0.96) | CYP2B6TBXAS1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL8164980 | 0.82 | CYP2B6 (0.46) | CYP2B6TBXAS1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL20076324 | 0.81 | CYP2B6 (1.00) | CYP2B6TBXAS1CYP19A1 | |
| SCHEMBL570574 | 0.81 | CYP2B6 (1.00) | CYP2B6TBXAS1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289753-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2022-09-15 | — | — | US | disclosed |
| EP-1812445-B1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LTD (GB) | 2015-12-30 | — | — | EP | disclosed |
| US-8946217-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-03 | — | — | US | disclosed |
| EP-2470021-B1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2014-10-22 | — | — | EP | disclosed |
| EP-2470021-B1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2014-10-22 | — | — | EP | disclosed |
| US-20140294946-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-02 | — | — | US | disclosed |
| US-20140275017-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275017-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8778957-B2 | CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778957-B2 | CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-07-15 | — | — | US | disclosed |
| CN-101679440-A | Pyrrolopyrimidine derivatives as jak3 inhibitors | PALAU PHARMA SA | 2010-03-24 | — | — | CN | disclosed |
| EP-2142550-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | Palau Pharma, S.A. (ES) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119792-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S. A. (ES) | 2008-10-09 | — | — | WO | disclosed |
| US-20080207611-A1 | Pharmaceutical compounds | PLRAMED LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| CN-101087794-A | Pharmaceutical compounds | PIRAMED LTD (GB) | 2007-12-12 | — | — | CN | disclosed |
| US-6362188-B1 | ANTICANCER AGENTS | SCHERING CORPORATION | 2002-03-26 | — | — | US | disclosed |
| US-4605744-A | ANTIBIOTICS | HOFFMANN-LA ROCHE INC. (US) | 1986-08-12 | — | — | US | disclosed |
| US-4537969-A | AZOLE-SUBSTITUTED SATURATED HETEROCYCLIC CARBOXALDEHYDE ACETALS;INTERMEDIATES FOR 6-AMIDINOPENICILLINS | HOFFMANN-LA ROCHE INC. (US) | 1985-08-27 | — | — | US | disclosed |
| EP-0148283-A1 | Novel penicillanic acid derivatives | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1985-07-17 | — | — | EP | disclosed |
| US-4431653-A | ANTIBIOTICS; BACTERICIDES; SSYNERGISTIC WITH AMINO ACID DERIVATIVE | HOFFMANN-LA ROCHE INC. (US) | 1984-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294946-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, JAK2, PIK3R1 | CYP2B6 678/4885TBXAS1 88/4885CYP19A1 113/4885 |
| US-20140275017-A1 | CGRP RECEPTOR ANTAGONISTS | BDKRB1, CALCRL, BDKRB2 | CYP2B6 1324/4885TBXAS1 521/4885CYP19A1 1206/4885 |
| US-20220289753-A1 | SHP2 INHIBITORS | PTPN1, PTPN2, PTPN7 | CYP2B6 3438/4885TBXAS1 2042/4885CYP19A1 3186/4885 |
| US-20080207611-A1 | Pharmaceutical compounds | PIK3CA, JAK2, PIK3R1 | CYP2B6 681/4885TBXAS1 86/4885CYP19A1 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.